Literature DB >> 3177405

Recombinant alpha 2 interferon-related cardiomyopathy.

M C Cohen1, M S Huberman, R W Nesto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3177405     DOI: 10.1016/s0002-9343(88)80094-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  14 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results.

Authors:  M Mirić; J Vasiljević; M Bojić; Z Popović; N Keserović; M Pesić
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

3.  Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma.

Authors:  Jennifer Rauw; Shaheeda Ahmed; Teresa Petrella
Journal:  Med Oncol       Date:  2011-04-17       Impact factor: 3.064

4.  Reversible cardiomyopathy in a patient with hairy cell leukaemia.

Authors:  G T Sucak; R Haznedar; R Yalçin
Journal:  Postgrad Med J       Date:  1998-05       Impact factor: 2.401

5.  Interferon-associated left ventricular dysfunction in a liver transplant recipient.

Authors:  R Mateo; S Jethmalani; D C Angus; J Gorcsan; B Uretsky; J Fung
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

6.  Reversible cardiomyopathy induced by interferon.

Authors:  M Sonnenblick; D Rosenmann; A Rosin
Journal:  BMJ       Date:  1990-05-05

7.  Effects of interleukin 2 on cardiac function in the isolated rat heart.

Authors:  P A Sobotka; J McMannis; R I Fisher; D G Stein; J X Thomas
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

8.  Interferon regulatory factors in heart: stress response beyond inflammation.

Authors:  Haipeng Sun; Yibin Wang
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

9.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.